Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 2022-2028

  Yeo, Lorraine ^a   Toellner, Kai Michael ^a   Salmon, Mike ^a   Filer, Andrew ^a,b   Buckley, Christopher D ^a,b   Raza, Karim ^a,b   Scheel Toellner, Dagmar ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APRIL GENE; ARTICLE; B LYMPHOCYTE; BAFF GENE; CCL2 GENE; CCL3 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL8 GENE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCATION; HUMAN; HUMAN CELL; IFN GAMMA GENE; IL12P35 GENE; IL12P40 GENE; IL17 GENE; IL18 GENE; IL1BETA GENE; IL2 GENE; IL21 GENE; IL23P19 GENE; IL27 GENE; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; MALE; MARKER GENE; MICROFLUIDIC ANALYSIS; NEUTROPHIL; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; RANKL GENE; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SYNOVIAL FLUID LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RANK LIGAND; RNA, MESSENGER; SYNOVIAL MEMBRANE; T-LYMPHOCYTE SUBSETS;

EID: 80053576370     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.153312     Document Type: Article

References (50)

1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.
2. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19. (Pubitemid 351986171)
3. van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther 2009;11:250.
4. Ehrenstein MR, Mauri C. If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. J Exp Med 2007;204:2249-52. (Pubitemid 47529311)
5. Brennan F M, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7. (Pubitemid 19180612)
6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
7. Combe B, Pope RM, Fischbach M, et al. Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 1985;59:520-8. (Pubitemid 15127600)
8. Firestein G S, Xu WD, Townsend K, et al. Cytokines in chronic infl ammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988;168:1573-86. (Pubitemid 19023248)
9. Smeets T J, Dolhain RJEM, AM, et al. Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1998;88:84-90.
10. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinfl ammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70. (Pubitemid 29215007)
11. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52. (Pubitemid 29218305)
12. Field M, Chu C, Feldmann M, et al. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991;11:45-50.
13. Chu C Q, Field M, Feldmann M, et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
14. Crotti T N, Smith MD, Weedon H, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-54. (Pubitemid 35397349)
15. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80. (Pubitemid 32660867)
16. Weyand C M, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. A rthritis Res Ther 2005;7(Suppl 3):S9-12.
17. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801. (Pubitemid 19011590)
18. Llorente L, Richaud-Patin Y, Fior R, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994;37:1647-55.
19. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50. (Pubitemid 35154008)
20. Wood N C, Dickens E, Symons JA, et al. In situ hybridization of interleukin-1 in CD14- positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992;62:295-300.
21. Tanaka M, Harigai M, Kawaguchi Y, et al. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol 2001;28:1779-87. (Pubitemid 32726923)
22. van Roon J A, Hartgring SA, Wenting-van Wijk M, et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:664-9. (Pubitemid 46707137)
23. van Holten J, Smeets TJ, Blankert P, et al. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005;64:1780-2. (Pubitemid 41667156)
24. Stamp L K, Easson A, Pettersson L, et al. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol 2009;36:2403-8.
25. Gabay C, Krenn V, Bosshard C, et al. Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 2009;11:R144.
26. Seyler T M, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115:3083-92. (Pubitemid 41567573)
27. Beaulieu AD, McColl SR. Differential expression of two major cytokines produced by neutrophils, interleukin-8 and the interleukin-1 receptor antagonist, in neutrophils isolated from the synovial fl uid and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1994;37:855-9.
28. Assi L K, Wong SH, Ludwig A, et al. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infi ltrating the rheumatoid joint. Arthritis Rheum 2007;56:1776-86. (Pubitemid 47110377)
29. Quayle J A, Adams S, Bucknall RC, et al. Cytokine expression by infl ammatory neutrophils. FEMS Immunol Med Microbiol 1994;8:233-9. (Pubitemid 24097634)
30. Hatano Y, Kasama T, Iwabuchi H, et al. Macrophage inflammatory protein 1 alpha expression by synovial fl uid neutrophils in rheumatoid arthritis. Ann Rheum Dis 1999;58:297-302. (Pubitemid 29232142)
31. Cohen S B, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309. (Pubitemid 351705919)
32. Arnett F C, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
33. Wei L, Laurence A, Elias KM, et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007;282:34605-10. (Pubitemid 350232469)
34. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
35. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439-46. (Pubitemid 27414801)
36. Airoldi I, Guglielmino R, Carra G, et al. The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes. Haematologica 2002;87:434-42. (Pubitemid 34297552)
37. Brentano F, Ospelt C, Stanczyk J, et al. A bundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2009;68:143-50.
38. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-18. (Pubitemid 32954353)
39. Evans J G, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007;178:7868-78. (Pubitemid 46898059)
40. Mauri C, Gray D, Mushtaq N, et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501. (Pubitemid 36278604)
41. Shigeyama Y, Pap T, Kunzler P, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
42. Skoumal M, Kolarz G, Haberhauer G, et al. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fl uid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005;26:63-9. (Pubitemid 41531517)
43. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46:1744-53. (Pubitemid 34774505)
44. Gravallese E M, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8. (Pubitemid 30395732)
45. Kong Y Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
46. Ehrhardt G R, Hijikata A, Kitamura H, et al. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med 2008;205:1807-17.
47. Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006;169:987-98. (Pubitemid 44411961)
48. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40. (Pubitemid 36418398)
49. Manzo A, Bombardieri M, Humby F, et al. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from infl ammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010;233:267-85.
50. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.